WEBVTT

1
00:00:00.240 --> 00:00:02.310
- Eli Lilly announced today that the drug

2
00:00:02.310 --> 00:00:03.780
behind Zep was found

3
00:00:03.780 --> 00:00:06.810
to help cut heart failure
risk in patients with obesity.

4
00:00:06.810 --> 00:00:09.120
In a late stage clinical trial,

5
00:00:09.120 --> 00:00:11.190
the medication Tirzepatide is sold

6
00:00:11.190 --> 00:00:14.250
by the company in the United
States as Mounjaro for diabetes

7
00:00:14.250 --> 00:00:15.840
and Zep bound for weight loss.

8
00:00:15.840 --> 00:00:19.260
The trial involves 731
participants with obesity

9
00:00:19.260 --> 00:00:21.930
and heart failure with
preserved ejection fraction,

10
00:00:21.930 --> 00:00:24.120
a condition where the heart's
left ventricle doesn't

11
00:00:24.120 --> 00:00:26.730
contract normally and
results in not enough blood

12
00:00:26.730 --> 00:00:28.380
circulating in the body.

13
00:00:28.380 --> 00:00:31.200
Half of the group was given
tirzepatide over the course

14
00:00:31.200 --> 00:00:34.650
of 52 weeks while the other
half was given a placebo.

15
00:00:34.650 --> 00:00:38.010
Patients who received
tirzepatide were 38% less likely

16
00:00:38.010 --> 00:00:39.510
to be hospitalized,

17
00:00:39.510 --> 00:00:41.670
need an increase in their
heart failure medication,

18
00:00:41.670 --> 00:00:44.400
or die of heart complications
compared to patients

19
00:00:44.400 --> 00:00:46.140
who were given a placebo.

20
00:00:46.140 --> 00:00:48.450
Eli Lilly's stock jumped nearly 4%

21
00:00:48.450 --> 00:00:50.220
during Wednesday pre-market trading.

22
00:00:50.220 --> 00:00:53.045
Following the news, the Pharma
Giant said that it plans

23
00:00:53.045 --> 00:00:54.900
to submit the results to the US Food

24
00:00:54.900 --> 00:00:57.180
and Drug Administration later this year,

25
00:00:57.180 --> 00:00:59.430
which could lead the agency
to expand the approved use

26
00:00:59.430 --> 00:01:01.860
of the drug to include
treating heart failure

27
00:01:01.860 --> 00:01:03.930
that could open access to the medication.

28
00:01:03.930 --> 00:01:06.300
If regulators expand the
approved use of Z Bound,

29
00:01:06.300 --> 00:01:09.360
the medication could join
Novo Nordisk Wegovy in being

30
00:01:09.360 --> 00:01:11.040
covered by Medicare.

31
00:01:11.040 --> 00:01:12.840
In March, the US Centers for Medicare

32
00:01:12.840 --> 00:01:15.000
and Medicaid Services
issued a new guidance

33
00:01:15.000 --> 00:01:18.870
that anti-obesity medications
that receive FDA approval

34
00:01:18.870 --> 00:01:21.330
for an additional
medically accepted use can

35
00:01:21.330 --> 00:01:22.770
be covered by Medicare.

36
00:01:22.770 --> 00:01:26.130
Earlier this year. Eli Lilly
said Tirzepatide was also found

37
00:01:26.130 --> 00:01:28.950
to help alleviate sleep
apnea in a separate late

38
00:01:28.950 --> 00:01:30.600
stage clinical trial.

39
00:01:30.600 --> 00:01:32.370
I'm Bruce Gale reporting for courts.

40
00:01:32.370 --> 00:01:34.680
Thanks for watching and stick with qz.com.